Gilead outlines 2026 base business sales of $29.8B-$30.1B while raising HIV growth outlook to 9%-10% (NASDAQ:GILD)August 5, 2026
Rio Tinto’s $3B asset sale lures private equity giants including Blackstone, KKR – report (RIO:NYSE)August 5, 2026
Share Facebook Twitter LinkedIn Pinterest Email Daiichi Sankyo-AstraZeneca gets BLA approved for lung cancer therapy in the U.S.
Gilead outlines 2026 base business sales of $29.8B-$30.1B while raising HIV growth outlook to 9%-10% (NASDAQ:GILD)August 5, 2026
Rio Tinto’s $3B asset sale lures private equity giants including Blackstone, KKR – report (RIO:NYSE)August 5, 2026
Booking projects Q3 2026 room nights up 3%-5% amid Middle East-related flight capacity pressure (NASDAQ:BKNG)August 4, 2026
By Press Room
By Press Room
By Press Room
